The resolution — proposed by six state medical societies — argues direct-to-consumer ads encourage patients to pressure their physicians into prescribing newer, more expensive medications. AMA’s policymaking body — the House of Delegates — will vote on the resolution during the association’s annual meeting in Chicago next week, according to STAT.
“[I]n a free enterprise system such as we have in the United States, the purchasing public should be educated,” the AMA resolution reads. “[A]dvertising should be required to state the manufacturer’s suggested retail price of those drugs.”
In 2015, AMA unsuccessfully attempted to convince lawmakers to institute a ban on direct-to-consumer advertising for prescription drugs all together.
More articles on supply chain:
AstraZeneca divests migraine drug for $302M
Advocacy group calls for FDA action on Bayer’s birth control device
Walmart pledges to slash supply chain greenhouse gas emission by 1B tons
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.